A randomized clinical study comparing the plaque inhibition effect of a SnF2/SHMP dentifrice (blend-a-med EXPERT GUMS PROTECTION) and a chlorhexidine digluconate dentifrice (Lacalut Aktiv).
OBJECTIVE
To compare the plaque inhibition benefits of a control 0.454% stannous fluoride/sodium hexametaphosphate/sodium fluoride dentifrice (SnF2/SHMP with 1450 ppm F) to a chlorhexidine digluconate (0.05%), aluminum lactate (0.8%), and aluminum fluoride (AlF3/Chx with 1400 ppm F) dentifrice.


METHODS
Twenty-nine subjects were randomized to a two-period, two-treatment, double-blind crossover sequence using blend-a-med EXPERT GUMS PROTECTION toothpaste (SnF2/SHMP) and Lacalut Aktiv toothpaste (AlF3/Chx). Each treatment was used along with a standard manual toothbrush (Oral-B P35 Indicator) for 17 days. Digital plaque image analysis (DPIA) was used at the end of each period for three consecutive days to evaluate plaque levels; a) overnight (A.M. pre-brush); b) following 40 seconds of brushing with the test product (A.M. post-brush); and c) mid-afternoon (P.M.). Images were analyzed using an objective computer algorithm to calculate the total area of visible plaque. A four-day washout period was instituted for the crossover phase.


RESULTS
Twenty-seven subjects completed the study. The SnF2/SHMP dentifrice provided a statistically significant lower level of plaque area coverage compared to the AlF3/Chx dentifrice at all time points. For the SnF2/SHMP dentifrice, plaque coverage was 19.4% lower (p = 0.0043) at the A.M. pre-brush, 25.6% lower (p = 0.0014) at the A.M. post-brush, and 19.8% lower (p = 0.0057) at the P.M. measure relative to the AlF3/Chx dentifrice.


CONCLUSIONS
The blend-a-med EXPERT GUMS PROTECTION toothpaste inhibits plaque regrowth, both overnight and during the day, to a significantly greater degree than Lacalut Aktiv. Additionally, immediately after brushing with blend-a-med EXPERT GUMS PROTECTION, subjects had significantly less plaque than after brushing with Lacalut Aktiv.
Bellamy
P G
PG
Procter & Gamble London Innovation Centre, Egham, Surrey, UK. bellamy.pg@pg.com
Khera
N
N
Day
T N
TN
Mussett
A J
AJ
Barker
M L
ML
D000328:Adult; D017607:Aluminum Compounds / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D002710:Chlorhexidine / Q000627:therapeutic use; D018592:Cross-Over Studies; D003773:Dental Plaque / Q000517:prevention & control*; D003802:Dentifrices / Q000737:chemistry / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D005459:Fluorides / Q000627:therapeutic use; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007773:Lactates / Q000627:therapeutic use; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000627:therapeutic use; D012969:Sodium Fluoride / Q000627:therapeutic use; D014002:Tin Fluorides / Q000627:therapeutic use
D017607:Aluminum Compounds; D000891:Anti-Infective Agents, Local; D003802:Dentifrices; D004338:Drug Combinations; D007773:Lactates; D010710:Phosphates; D014002:Tin Fluorides; D012969:Sodium Fluoride; C009285:sodium polymetaphosphate; D005459:Fluorides; D002710:Chlorhexidine; C104223:aluminum lactate; C032311:aluminum fluoride